DEVELOPMENT AND LICENSE AGREEMENT BY AND BETWEEN BIOCRYST PHARMACEUTICALS, INC. AND AND HOFFMANN-LA ROCHE INC.Development and License Agreement • December 22nd, 2005 • Biocryst Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Delaware
This Development and License Agreement (this “Agreement") dated as of November 29, 2005 (“Effective Date") is made by and between BioCryst Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware having an office and place of business at 2190 Parkway Lake Drive, Birmingham, Alabama 35244 (“BioCryst"), on one hand, and on the other hand F.Hoffmann-La Roche Ltd, a corporation of Switzerland having its principle office at Grenzacherstrasse 124, CH-4070, Basel, Switzerland (“Roche-Basel") and Hoffmann-La Roche Inc., a New Jersey corporation having its principle place of business at 340 Kingsland Street, Nutley, New Jersey 07110 (“Roche-Nutley") (Roche-Nutley and Roche-Basel are collectively referred to as “Roche").
